Ftse Mib
38.421,05
0,00%
DAX
22.287,56
-0,24%
S&P 500
6.013,13
-1,71%
NASDAQ
19.524,01
-2,20%
Bitcoin
95.814,00
-0,48%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Akari Therapeutics PLC (AKTX) Akari Therapeutics PLC (AKTX) Notizie

AKTX

Akari Therapeutics (AKTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKTX
DataOraFonteTitoloSimboloCompagnia
19/02/202515:00GlobeNewswire Inc.Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceNASDAQ:AKTXAkari Therapeutics PLC
14/02/202523:00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
07/02/202522:30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
03/02/202514:00GlobeNewswire Inc.Akari Therapeutics Joins Webull Corporate Connect Service PlatformNASDAQ:AKTXAkari Therapeutics PLC
13/01/202514:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
13/01/202514:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKTXAkari Therapeutics PLC
26/12/202422:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKTXAkari Therapeutics PLC
18/12/202414:51GlobeNewswire Inc.Akari Therapeutics Announces Key Leadership AppointmentsNASDAQ:AKTXAkari Therapeutics PLC
16/12/202415:05GlobeNewswire Inc.Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial OfficerNASDAQ:AKTXAkari Therapeutics PLC
06/12/202422:00Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
19/11/202422:48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKTXAkari Therapeutics PLC
15/11/202422:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AKTXAkari Therapeutics PLC
15/10/202414:51Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
11/10/202422:52Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AKTXAkari Therapeutics PLC
09/10/202422:27Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
16/09/202422:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKTXAkari Therapeutics PLC
16/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AKTXAkari Therapeutics PLC
13/09/202423:30Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:AKTXAkari Therapeutics PLC
06/09/202423:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AKTXAkari Therapeutics PLC
23/08/202422:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
20/06/202413:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AKTXAkari Therapeutics PLC
18/06/202422:15Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AKTXAkari Therapeutics PLC
03/06/202422:21Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AKTXAkari Therapeutics PLC
15/03/202417:53PR Newswire (US)Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law FirmNASDAQ:AKTXAkari Therapeutics PLC
09/01/202423:25Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AKTXAkari Therapeutics PLC
01/12/202314:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AKTXAkari Therapeutics PLC
20/10/202322:29Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AKTXAkari Therapeutics PLC
20/10/202322:23Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:AKTXAkari Therapeutics PLC
12/10/202322:43Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKTXAkari Therapeutics PLC
07/06/202312:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AKTXAkari Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKTX

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci